

Referral Support Service

Gynaecology

GY10 Polycystic Ovarian Syndrome

Definition

- PCOS is a common endocrine disorder, with a prevalence of 6-7% of population. It is characterized by ovulatory failure and hyperandrogenism; causing oligomenorrhoea, hirsuitism, acne and subfertility. (USS features of polycystic ovaries can be found in upto 20% of women, but the syndrome is only diagnosed with clinical features)
- Longer term sequelae include; Type 2 DM, cardio-metabolic syndrome, obesity and sleep apnoea.

Investigations

- History: establish clinical features, such as acne, hirsuitism, irregular periods, subfertility
- Examination: BMI, hirsuitism, presence of acne.
- Investigations:
 - baseline USS
 - o Bloods: TFTs, Prolactin, FSH/LH (D1-5), Free Androgen Index
 - A raised free testosterone is more clinically significant than the traditional FSH/LH ratio for diagnostic purposes.

Exclude Red Flag Symptoms

- Endometrial Hyperplasia and carcinoma risk is elevated in this cohort, particularly when associated with < 4 periods a year (in the absence of hormonal therapy). Sudden changes in bleeding pattern over age 40 should be regarded as higher risk, consider early referral.
- Androgen-Secreting Tumours: a female with a total testosterone level >5nmol/L should be referred for further investigations.

Management

- Subfertility: Please refer to the subfertility guideline, which supports early referral for patients with oligomenorrhoea, with a BMI under 35, for consideration of clomiphene therapy or ovarian driling.
- Oligomenorrhoea: general advice for any woman with PCOS is to ensure 4 withdrawal bleeds a year to prevent endometrial hyperplasia. This may be using any hormonal form of contraceptive.
- The Mirena offers excellent endometrial protection and contraception.
- If contraception is not required, then quarterly courses of progesterone e.g. Norethisterone 5mg tds for 10d to induce menses is recommended.
- The RCOG patient info sheet is a fantastic resource to guide patients.
- Symptoms of hyperandrogenism:
 - Weight loss- particularly if BMI >25 can improve sx

Responsible GP: Responsible Consultant: Date published: 2013 Review date: Sept 2024



- COCP- all will help reduce androgen levels, but Dianette, which contains cyproterone acetate, may yield quicker improvement, then consider conversion to a standard COCP after a year. Yasmin, is a second line COCP licensed for acne management.
- Topical agents containing effornithine; Vaniqa
- Unlicensed therapies include: spironolactone and anti-androgens, but specialist advice should be sought to support the use of these agents.
- Longterm Risks: All patients should be given lifestyle advice on PCOS, about importance of healthy eating and exercise, but they should also be counselled about the 10-20% risk of T2DM and need for annual screening after age 40, with HbA1c levels.

Referral Information

Diagnosis

Two out of three of the following criteria should be met

- 1. USS findings of polycystic ovaries (12+ peripheral "string of pearls" cycts)
- 2. Oligo or Anovulation
- 3. Biochemical or clinical features of hyperandrogenism

Essential information for Referral

- History should state if advice sought on diagnostic uncertainty, symptom management or subfertility input
- Hormone profile
- USS result
- Current contraception and parity
- Smear history
- Treatments options please indicate which tried, effective or contraindications exist
 - o Mirena
 - COCP
- Relevant past medical/surgical history
- Current regular medication
- BMI (Under 35 for surgery) and smoking status

Patient information leaflets/ PDAs

RCOG PILS PatientUK

References

RCOG Long term Consequences of PCOS- please click here